An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA: Original Article

Journal of Internal Medicine

Volumn 267, Issue 3, 2010, Pages 316-321

  Cervin, C ^a   Axler, O ^b   Holmkvist, J ^a,c   Almgren, P ^a   Rantala, E ^d,e   Tuomi, T ^d,e,f   Groop, L ^a   Dahlback B ^b   Karlsson, E ^a  

^a AstraZeneca LP   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c STENO DIABETES CENTER   (Denmark)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f FOLKHÄLSAN RESEARCH CENTER   (Finland)

Author keywords

Apolipoprotein M; Hepatocyte nuclear factor; Maturity onset diabetes of the young

Indexed keywords

APOLIPOPROTEIN M; CHOLESTEROL; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FINLAND; GENE INSERTION; HETEROZYGOTE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MATURITY ONSET DIABETES MELLITUS; MATURITY ONSET DIABETES MELLITUS 1; MATURITY ONSET DIABETES MELLITUS 3; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; APOLIPOPROTEINS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; SEX FACTORS;

EID: 75749155017     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02145.x     Document Type: Article

References (24)

1. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001 345 : 971 980.
2. Baumhueter S, Mendel DB, Conley PB et al. HNF-1 shares three sequence motifs with the POU domain proteins and is identical to LF-B1 and APF. Genes Dev 1990 4 : 372 379. (Pubitemid 120012620)
3. Pontoglio M, Barra J, Hadchouel M et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996 84 : 575 585.
4. Weber H, Holewa B, Jones EA, Ryffel GU. Mesoderm and endoderm differentiation in animal cap explants: identification of the HNF4-binding site as an activin A responsive element in the Xenopus HNF1alpha promoter. Development 1996 122 : 1975 1984.
5. Yamagata K. Regulation of pancreatic beta-cell function by the HNF transcription network: lessons from maturity-onset diabetes of the young (MODY). Endocr J 2003 50 : 491 499.
6. Timsit J, Bellanne-Chantelot C, Dubois-Laforgue D, Velho G. Diagnosis and management of maturity-onset diabetes of the young. Treat Endocrinol 2005 4 : 9 18.
7. Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 1999 274 : 31286 31290.
8. Ahnstrom J, Faber K, Axler O, Dahlback B. Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M. J Lipid Res 2007 48 : 1754 1762.
9. Duan J, Dahlback B, Villoutreix BO. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett 2001 499 : 127 132.
10. Faber K, Hvidberg V, Moestrup SK, Dahlback B, Nielsen LB. Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. Mol Endocrinol 2006 20 : 212 218.
11. Axler O, Ahnstrom J, Dahlback B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 2007 48 : 1772 1780.
12. Deakin JE, Papenfuss AT, Belov K et al. Evolution and comparative analysis of the MHC Class III inflammatory region. BMC Genomics 2006 7 : 281.
13. Richter S, Shih DQ, Pearson ER et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003 52 : 2989 2995.
14. Groop L, Forsblom C, Lehtovirta M et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 1996 45 : 1585 1593.
15. Lehto M, Tuomi T, Mahtani MM et al. Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect. J Clin Invest 1997 99 : 582 591.
16. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 15 : 539 553.
17. Skupien J, Kepka G, Gorczynska-Kosiorz S et al. Evaluation of apolipoprotein M serum concentration as a biomarker of HNF-1alpha MODY. Rev Diabet Stud 2007 4 : 231 235.
18. Christoffersen C, Jauhiainen M, Moser M et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 2008 283 : 1839 1847.
19. Odom DT, Dowell RD, Jacobsen ES et al. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat Genet 2007 39 : 730 732.
20. Calayir E, Becker TM, Kratzer A et al. LXR-agonists regulate ApoM expression differentially in liver and intestine. Curr Pharm Biotechnol 2008 9 : 516 521.
21. Zhang X, Zhu Z, Luo G, Zheng L, Nilsson-Ehle P, Xu N. Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. Biochem Biophys Res Commun 2008 371 : 114 117.
22. Wolfrum C, Howell JJ, Ndungo E, Stoffel M. Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M. J Biol Chem 2008 283 : 16940 16949.
23. Venteclef N, Haroniti A, Tousaint J-J, Talianidis I, Delerive P. Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1. J Biol Chem 2008 283 : 3694 3701.
24. Freeman LA, Kennedy A, Wu J et al. The orphan nuclear receptor LRH-1 activates the ABCG5/ABCG8 intergenic promoter. J Lipid Res 2004 45 : 1197 1206.